|
Back to EZorb Newsletter Index |
|
In this issue:
1. Share Success: Letters From Readers Letter I: From Shirley S. Hi my name is Shirley. I'm 77 years old, female. I have Degenerative arthritis, have had one Synvisc-One injection done in 2021. On May 6,2022 I'm due to have Synvisc-One injection done on each knee. I do not want to have this done. I started taking EZorb on May 3,2022 took ten a day, 5 in the morning and 5 before bed for 8 weeks June 27,2022, on June 28 started taking 8 a day, 4 in the morning and 4 at bed time. I have bone on bone in my left knee and the right knee is bad also but not bone on bone. Since I've been taking EZorb I have noticed a big improvement in my knees. I can get up and down out of a chair with no pain. And my knees are feeling stronger, so if I reduce the amount of EZorb will I still get the right amount of EZorb that I need for my bones? So glad I did not get the knee injections on May 6,2022, both of my knees. I still have a way to go, its just going to take a little longer. Not giving up on EZorb cause I do see improvement. Letter II:
From Cheri D. Hi there, I am just wondering if you guys sell stock in your company, if so what is the stock name? I believe that your company is going to be really big some day. Everyone should be using Ezorb. It has helped me, my dad, my uncle and aunt. I'm going to continue to spread the word on the benefits of taking ezorb. What a great product! Thank you, Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life. Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public. 2. Research News: Viscosupplementation Ineffective for Knee OsteoarthritisFindings from a systematic review and meta-analysis indicate that viscosupplementation does not significantly improve pain and physical function in people with knee osteoarthritis, but increases the risk for serious adverse events. Bruno da Costa (University of Toronto, Ontario, Canada) and co-authors analyzed data from 25 placebo-controlled trials including a total of 9423 patients, finding that viscosupplementation – defined as intra-articular injection with any hyaluronic acid preparation or a hyaluronic acid derivative - achieved a “small, non-clinically relevant” decrease in pain intensity. Specifically, the pooled standardized mean difference (SMD) for viscosupplementation versus placebo was -0.08, and the lower bound of the 95% confidence interval excluded the minimal clinically important difference. These findings corresponded to a reduction in pain intensity of 2 mm on a 100 mm visual analog scale with viscosupplementation relative to placebo. Similarly, viscosupplementation resulted in a small improvement in physical function when compared with placebo, with an SMD of -0.11 that did not meet the threshold for clinical importance. Despite the lack of benefits with viscosupplementation, the study authors found that the procedure was associated with a significant 1.49-fold increased risk for serious adverse events relative to placebo, at rates of 3.7% versus 2.5%. “Our findings do not support the broad use of viscosupplementation for the treatment of knee osteoarthritis,” concludes the team in The BMJ. Original research was published in BMJ 2022; 378: e069722. 3. Useful LinksEZorb - Frequently Asked Questions & Answers 4. What Are Others Saying About EZorb and Marvlix?EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix. |
|
Back to EZorb Newsletter Index |